Showing 504 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across…
-
Press release /Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
-
Press release /In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1In a…
-
Press release /Results from year two of the Phase III KESTREL clinical trial confirmed year one findings, with an overall favorable benefit-risk profile for Beovu® (brolucizumab) 6 mg in patients with visual…
-
Press release /Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s…
-
Press release /Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo…
-
Press release /In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two…
-
Press release /New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Press release /In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
-
Press release /EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…